United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - trastuzumab - powder for solution for infusion - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - trastuzumab - solution for injection - 120mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - trastuzumab - powder for solution for infusion - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - trastuzumab - powder for solution for infusion - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - trastuzumab - powder for solution for infusion - 150mg

Singapore - English - HSA (Health Sciences Authority)

celltrion healthcare singapore private limited - trastuzumab - injection, powder, lyophilized, for solution - trastuzumab 150 mg/vial

Singapore - English - HSA (Health Sciences Authority)

celltrion healthcare singapore private limited - trastuzumab - injection, powder, lyophilized, for solution - trastuzumab 440 mg/vial

Israel - English - Ministry of Health

amgen europe b.v. - trastuzumab - powder for concentrate for solution for infusion - trastuzumab 150 mg/vial - trastuzumab - metastatic breast cancer (mbc)kanjinti is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress her2;1. as a single agent, for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease.2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.3. in combination with an aromatase inhibitor for the treatment of postmenopausal patient with hormone-receptor positive metastatic breast cancer.early breast cancer (ebc)kanjinti is indicated to treat patients with her2 positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines.kanjinti should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.kanjinti should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc 2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.

Israel - English - Ministry of Health

amgen europe b.v. - trastuzumab - powder for concentrate for solution for infusion - trastuzumab 420 mg/vial - trastuzumab - metastatic breast cancer (mbc)kanjinti is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress her2;1. as a single agent, for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease.2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.3. in combination with an aromatase inhibitor for the treatment of postmenopausal patient with hormone-receptor positive metastatic breast cancer.early breast cancer (ebc)kanjinti is indicated to treat patients with her2 positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines.kanjinti should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.kanjinti should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc 2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.

Israel - English - Ministry of Health

unipharm trading ltd, israel - trastuzumab - powder and solvent for concentrate for solution for infusion - trastuzumab 420 mg/vial - trastuzumab - herity is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease.2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.3. herity in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer.early breast cancer (ebc) :herity is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines.herity should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc). herity in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.herity should only be used in patients with metastatic gastric cancer whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.